Clinical trials: Mental Depression
Major Depressive Disorder
An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients
The primary objective of this study is to evaluate the efficacy of 3 fixed doses of SSR411298 (10, 50 or 200 mg daily) compared to placebo, in elderly patients with Major Depressive Disorder (MDD), based on the 17-item Hamilton…
- Trial name
- FIDELIO (NCT00822744)
- Testing
- SSR411298, Escitalopram
- Where
- 7 sites in Chile, Mexico and 5 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Premenstrual Syndrome (PMS)
Oxaloacetate Supplementation for Emotional PMS
Emotional Premenstrual Syndrome (PMS) affects millions of women worldwide. For Emotional PMS, including depression, anxiety, perceived stress and aggression, there are very few options.
- Trial name
- OAA4PMS (NCT03509714)
- Testing
- Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)
- Volunteers
- 48 people
- Sponsor
- Terra Biological LLC
Major Depressive Disorder
A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder
The primary purpose of this study is to assess whether at least 1 dose of LY2216684 (12 milligrams [mg] or 18 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with major depressive…
- Trial name
- NCT01173601
- Testing
- LY2216684, SSRI
- Where
- 63 sites in United States, Japan and 5 more
- Volunteers
- 1,416 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Recurrent, Unspecified
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
- Trial name
- NCT02271412
- Testing
- LY03005
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Adjunctive Treatment of Major Depressive Disorder
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major Depressive Disorder (MDD) participants currently treated with antidepressant therapy.
- Trial name
- NCT04103892
- Testing
- CLE-100
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 146 people
- Sponsor
- Clexio Biosciences Ltd.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111565
- Testing
- Escitalopram, Aripiprazole
- Where
- 53 sites in United States, Canada and 9 more
- Volunteers
- 137 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Anxiety, Depression
A Randomized-Controlled Trial to Investigate the Effect of a Novel Music Therapy Application to Reduce Anxiety and Stress
This virtual, open-label, three-group, randomized-controlled trial will last six weeks. Participants will be allocated into three groups; the Intervention Group, Spotify Group, and Control Group.
- Conditions
- Anxiety, Depression, Stress
- Trial name
- NCT06021821
- Testing
- SoundMind App, Spotify Playlist
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- SoundMind
Schizophrenia
Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia
Part 1 of the study will assess the enhancement of task-related brain activation (BOLD response) in key brain areas in schizophrenia during the performance of working memory, episodic memory and visual activation tasks as…
- Trial name
- NCT00825539
- Testing
- AQW051
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Depression
Clinical Study on the Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression
This is a single center phase I / II clinical trial. Randomized, blind and positive drug parallel control were used to evaluate the safety and effectiveness of dental pulp mesenchymal cell injection in the treatment of depression…
- Trial name
- NCT05127369
- Testing
- Dental pulp mesenchymal cell injection, Dental pulp mesenchymal cell vehicle, fluoxetine hydrochloride capsule
- Volunteers
- 48 people
- Sponsor
- CAR-T (Shanghai) Biotechnology Co., Ltd.
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111539
- Testing
- Escitalopram, Aripiprazole, Blinded capsule
- Where
- 62 sites in United States, Estonia and 7 more
- Volunteers
- 211 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, MDD
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant…
- Conditions
- Major Depressive Disorder, MDD, Depression
- Trial name
- NCT01152554
- Testing
- TC-5214
- Where
- 94 sites in United States, Puerto Rico
- Volunteers
- 813 people
- Sponsor
- AstraZeneca
Bipolar Disorder
Bipolar Disorder Study for Men and Women
A Placebo Controlled Study Evaluating Efficacy and Safety of Medication in Patients with Bipolar Disorder
- Trial name
- NCT00056277
- Testing
- lamotrigine
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Seasonal Affective Disorder
30-Minute Light Exposure for the Treatment of Seasonal Affective Disorder
The primary objective of this study is to evaluate the effect of light therapy using a narrow 467nm light compared to a 580nm light in subjects with Seasonal Affective Disorder (SAD).
- Trial name
- SAD (NCT01462305)
- Testing
- goLITE, Control
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Philips Respironics
Major Depressive Disorder
Oral Multiple-dose Study in Patients With Major Depressive Disorder
A study was to evaluate the safety and plasma concentration changes of quetiapine after repeated administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive disorder (MDD).
- Trial name
- NCT01924520
- Testing
- FK949E
- Where
- 2 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Astellas Pharma Inc
Postpartum Depression
Effect of Consuming a Combination of Probiotic Strains on Postpartum Depression
The objective of this trial is to evaluate the effect of consuming a combination of Lactobacillus during the pregnancy and lactation period on the incidence of postpartum depression.
- Trial name
- NCT06651424
- Testing
- Combination of Lactobacillus probiotics (no comercial)
- Where
- 3 sites in Spain
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Bipolar Depression
Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression
The purpose of the study is to evaluate the efficacy and safety of H1-Coil deep brain rTMS in subjects with bipolar depression, taking mood stabilizers and previously unsuccessfully treated with antidepressant medications.
- Trial name
- NCT01566591
- Testing
- Deep TMS Treatment
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 120 people
- Sponsor
- Brainsway
Depressive Disorder, Major
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 mg compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to…
- Trial name
- NCT02932943
- Testing
- Rapastinel
- Where
- 31 sites in United States
- Volunteers
- 465 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depression
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major…
- Trial name
- NCT01305408
- Testing
- Armodafinil
- Where
- 130 sites in United States, Argentina and 12 more
- Volunteers
- 399 people
- Sponsor
- Cephalon
Major Depressive Disorder
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder
This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder.
- Trial name
- NEST-MDD (NCT01370733)
- Testing
- NEST-1 (NeoSync EEG Synchronized TMS)
- Where
- 18 sites in United States
- Volunteers
- 202 people
- Sponsor
- Wave Neuroscience
Major Depressive Disorder
New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD).
- Trial name
- NCT06357832
- Testing
- Brainsway Deep TMS System
- Where
- 9 sites in United States, India and 1 more
- Volunteers
- 104 people
- Sponsor
- Brainsway
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.